
Spero Therapeutics Investor Relations Material
Latest events

Q4 2024
Spero Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Spero Therapeutics Inc
Access all reports
Spero Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for bacterial infections, including multi-drug-resistant bacterial infections. The company's pipeline includes both oral and intravenous antibiotic candidates designed to address serious and difficult-to-treat infections. Spero's lead programs target conditions such as urinary tract infections and hospital-acquired bacterial infections, with an emphasis on addressing the growing challenge of antibiotic resistance. The company’s research and development efforts aim to provide new therapeutic options in areas with high unmet medical needs. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
SPRO
Country
🇺🇸 United States